|
Document Type |
: |
Thesis |
|
Document Title |
: |
In Vitro Hepatitis C Virus Infectivity Inhibition by Defensin Peptides تثبيط نشاط فيروس إلتهاب الكبد الوبائي (ج) بواسطة بيبتيدات الدفنسين بإستخدام المزارع الخلوية |
|
Subject |
: |
Faculty of Sciences > biological sciences department |
|
Document Language |
: |
Arabic |
|
Abstract |
: |
Hepatitis C virus (HCV) is the major etiological agent of human non-A and non-B hepatitis, affecting about 180 million people worldwide. While the current standard of care for the treatment of HCV infection is ribavirin free and/or in combination with interferon-α (IFN-α), this therapeutic regimen presents several drawbacks, mainly related to efficacy limitation (~60%) and serious side effects, to resistance issues, and to the lack of efficacy for the treatment of specific viral genotypes. In 2011, the FDA approved two HCV-targeted antivirals, namely boceprevir and telaprevir which work directly on the virus molecules and proved to be effective in achieving sustained virological response rate up to 75%. However, problems associated with these therapeutic regimens still exist and need to be addressed, including the treatment course cost and the availability. HCV-infected patients, specifically in developing countries always seeking for available and low cost drugs. So, some of those patients often are looking for the alternative medicine.
Our experiences in the alternative anti-HCV drug research revealed that camel milk have some very promising proteins ingredients. The current study was planned to find other effective proteins against HCV. Defensins proteins were a strong candidate for that due to their well known anti-viral potentials and to their small molecular weight. The estimation of circulating α- and ß-defensins concentrations in both acute and chronic HCV-patients also was one of aim. The study was evaluated of two kinds of defensins (human (α- and ß–defensins) and synthetic animal alpha-defensins) through invitro tissue culture evaluation system with other techniques (RT-nested-PCR and real-time PCR). The results clearly revealed that chronic HCV-patients have a higher and significant defensins concentration than those of acute infection. Human α- and ß-defensins revealed a strong activity against HCV molecules at (cellular protection, neutralization and cellular treatment experiments) and at all concentrations were used (10, 20 and 50 µg). While the synthetic defensins could revealed similar anti-HCV potentials only at concentration (250µg) and could not shown any activity at 10 and 20 µg. Study conclude for first time that, the chronic HCV-patients contains higher concentration of defensins than acute HCV-patients. The defensins proteins are a strong invitro fighter against HCV. |
|
Supervisor |
: |
Prof. Dr. Elrashdy M. Redwan |
|
Thesis Type |
: |
Doctorate Thesis |
|
Publishing Year |
: |
1437 AH
2016 AD |
|
Added Date |
: |
Wednesday, June 1, 2016 |
|
Researchers
| إيهاب حسين مطر | Mattar, Ehab Hussain | Researcher | Doctorate | |
|